M. Kadri Altundağ

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer

Umar Raza, Özge Saatci, Stefan Uhlmann et al. · Oncotarget · 2016 · 58 citations · Full text

Epithelial-mesenchymal Transition, Breast Oncology, Oncology +14

Primary low grade B-cell lymphoma of the dura in an immunocompetent patient.

M. Kadri Altundağ, Fadıl Akyol, A. Uner · PubMed · 2000 · 52 citations

B-cell Lymphoma, Neuro-oncology, Immunocompetent Patient +11

A case report: zoledronic acid-induced anterior uveitis

Yasemin Özdamar, M. Kadri Altundağ, Ömer Dızdar · Medical Oncology · 2007 · 33 citations

Ocular Disease, Ophthalmology, Ocular Pathology +3

Effects of Growth Factors on Doxorubicin-Induced Skin Necrosis: Documentation of Histomorphological Alterations and Early Treatment by GM-CSF and G-CSF

İbrahim Vargel, Adnan Erdem, Dilek Ertoy et al. · Annals of Plastic Surgery · 2002 · 30 citations